Liver cancer and hepatic decompensation events in patients hospitalized with viral hepatitis in Spain
Tóm tắt
Chronic viral hepatitis B, C, and D are the main causes of decompensated cirrhosis and liver cancer worldwide. Newborn HBV vaccination was implemented more than 2 decades ago in most EU countries. Furthermore, potent oral antivirals have been available to treat HBV for 15 years and to cure HCV since 2014. The real-life clinical benefits of these interventions at country level have not been assessed, especially regarding major hepatic outcomes such as cirrhotic decompensation events and hepatocellular carcinoma (HCC). Retrospective study of all hospitalizations in Spain having HBV, HCV, and HDV as diagnosis using the Spanish National Registry of Hospital Discharges. Information was retrieved from 1997 up to 2017. From a total of 73,939,642 hospital admissions during the study period, a diagnosis of HBV, HCV, and HDV was made in 124,915 (1.7‰), 981,985 (13.3‰), and 4850 (0.07‰) patients, respectively. The median age of patients hospitalized within each group was 53.2, 55.9, and 47.0 years, respectively. Significant increases in mean age at hospitalization occurred in all groups (0.6 years older per calendar year on average). The overall rate of hepatic decompensation events for HBV, HCV, and HDV was 12.1%, 14.1%, and 18.8%, respectively. For HCC hospitalizations, these figures were 6.7%, 8.0%, and 7.8%, respectively. Whereas, the rate of decompensation events declined in recent years for HBV, and more recently for HCV, it continued rising up for HDV. Likewise, liver cancer rates recently plateaued for HBV and HCV, but kept growing for HDV. The rate of hepatic decompensation events and liver cancer has declined and/or plateaued in recent years for patients hospitalized with HBV and HCV infections, following the widespread use of oral antiviral therapies for these viruses. In contrast, the rate of decompensated cirrhotic events and HCC has kept rising up for patients with hepatitis delta, for which effective antiviral treatment does not exist yet.
Tài liệu tham khảo
Perez J, Armstrong G, Farrington L, Hutin Y, Bell B. The contributions of hepatitis B virus and hepatitis C virus infections to cirrhosis and primary liver cancer worldwide. J Hepatol. 2006;45:529–538
Mårdh O, Quinten C, Amato-Gauci A, Duffell E. Mortality from liver diseases attributable to hepatitis B and C in the EU/EEA—descriptive analysis and estimation of 2015 baseline. Infect Dis (Lond). 2020;52:625–637
Seto W, Lo Y, Pawlotsky JM, Yuen M. Chronic hepatitis B virus infection. Lancet. 2018;392:2313–2324
Tang L, Covert E, Wilson E, Kottilil S. Chronic hepatitis B infection: a review. JAMA. 2018;319:1802–1813
Poland G, Jacobson R. Clinical practice: prevention of hepatitis B with the hepatitis B vaccine. N Engl J Med. 2004;351:2832–2838
Terrault N, Lok A, McMahon B, et al. Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 chronic hepatitis B guidance. Hepatology. 2018;67:1560–1599
Spearman C, Dusheiko G, Hellard M, Sonderup M. Hepatitis C. Lancet. 2019;394:1451–1466
Thomas D. Global elimination of chronic hepatitis. N Engl J Med. 2019;380:2041–2050
Samarasekera U. Urgent action needed to eliminate viral hepatitis by 2030. Lancet Gastroenterol Hepatol. 2021;6:611
Soriano V, Sherman K, Barreiro P. Hepatitis delta and HIV infection. AIDS. 2017;31:875–884
Wedemeyer H, Manns MP. Epidemiology, pathogenesis and management of hepatitis D: update and challenges ahead. Nat Rev Gastroenterol Hepatol. 2010;7:31–40
Lempp F, Ni Y, Urban S. Hepatitis delta virus: insights into a peculiar pathogen and novel treatment options. Nat Rev Gastroenterol Hepatol. 2016;13:580–589
Stockdale A, Kreuels B, Henrion M, et al. The global prevalence of hepatitis D virus infection: systematic review and meta-analysis. J Hepatol. 2020;73:523–532
Toy M, Ahishali E, Yurdaydin C. Hepatitis delta virus epidemiology in the industrialized world. AIDS Rev. 2020;22:203–212
Loglio A, Ferenci P, Uceda-Renteria S, et al. Safety and effectiveness of up to 3 years’ bulevirtide monotherapy in patients with HDV-related cirrhosis. J Hepatol. 2022;76(2):464–9 (In press)
WHO. Combating hepatitis B and C to reach elimination by 2030. Geneva: WHO; 2016
Ministerio de Sanidad, Servicios Sociales e Igualdad. Real decreto 69/2015, de 6 febrero, por el que se regula el Registro de Actividad Sanitaria Especializada. Boletín del Estado 2015, 35, 1078–1080. Available online: http://www.boe.es/eli/es/rd/2015/02/06/69/con (Accessed on 15 Dec 2021)
Ramos JM, de Mendoza C, Aguilera A, et al. Hospital admissions in individuals with HTLV-1 infection in Spain. AIDS. 2020;34:1019–1027
López de Andrés A, Jiménez-García R, Hernández-Barrera V, et al. Sex-related disparities in the incidence and outcomes of hemorrhagic stroke among type 2 diabetes patients: a propensity score matching analysis using the Spanish National Hospital Discharge Database for the period 2016–18. Cardiovasc Diabetol. 2021;20:138
Ramos-Rincón JM, Menchi-Elanzi M, Pinargote-Celorio H, et al. Trends in hospitalizations and deaths in HIV-infected patients in Spain over two decades. AIDS. 2022;36:249–256
Ministerio de Sanidad y Consumo. Metodología de la hospitalización en el Sistema Nacional de salud. Available online: http://www.mscbs.gob.es/estadEstudios/estadisticas/docs/metod_modelo_cmbd_pub.pdf (accessed 15 Dec 2021)
Paik J, Golabi P, Younossi Y, Mishra A, Younossi Z. Changes in the global burden of chronic liver diseases from 2012 to 2017: the growing impact of NAFLD. Hepatology. 2020;72:1605–1616
Pimpin L, Cortez-Pinto H, Negro F, et al. Burden of liver disease in Europe: epidemiology and analysis of risk factors to identify prevention policies. J Hepatol. 2018;69:718–735
Aguilera A, Trastoy R, Rodriguez-Calvino J, Manso T, de Mendoza C, Soriano V. Prevalence and incidence of hepatitis delta in patients with chronic hepatitis B in Spain. Eur J Gastroenterol Hepatol. 2018;30:1060–1062
Liu K, Choi J, Le A, et al. Tenofovir disoproxil fumarate reduces hepatocellular carcinoma, decompensation and death in chronic hepatitis B patients with cirrhosis. Aliment Pharmacol Ther. 2019;50:1037–1048
Nozaki A, Chuma M, Hara K, et al. Sofosbuvir-based therapies associated with regression of liver fibrosis in patients with hepatitis C virus infection: a prospective observational study. Medicine (Baltimore). 2021;100: e25110
Ramos-Rincon JM, Pinargote H, de Mendoza C, et al. Hepatitis C hospitalizations in Spain and impact of new curative antiviral strategies. J Viral Hepat. 2022. https://doi.org/10.1007/s11908-022-00776-3
Soriano V, Mendoza C, Barreiro P, Treviño A, Corral O. Envisioning a hepatitis delta cure with new antivirals. Future Microbiol. 2021;16:927–930
Na J, Sinn D, Lee J, et al. Efficacy of entecavir versus tenofovir in preventing hepatocellular carcinoma in patients with chronic hepatitis B with maintained virologic response. J Viral Hepat. 2021;28:1392–1399
Choi W, Choi J, Lim Y. Effects of tenofovir vs entecavir on risk of hepatocellular carcinoma in patients with chronic HBV infection: a systematic review and meta-analysis. Clin Gastroenterol Hepatol. 2021;19:246–258
Lee H, Han D, Shin H, et al. Hepatocellular carcinoma risk according to regimens for eradication of hepatitis C virus; interferon or direct acting antivirals. Cancers (Basel). 2020;12:3414
Soriano V, Tefferi A. Prevention of liver cancer with new curative hepatitis C antivirals: real-world challenges. Cancer. 2018;124:1647–1649
Sezaki H, Borghi J, Cheung R, Enomoto M, Nguyen M. Hepatocellular carcinoma incidence with tenofovir versus entecavir in chronic hepatitis B: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol. 2020;5:1039–1052
Ginès P, Krag A, Abraldes J, Solà E, Fabrellas N, Kamath P. Liver cirrhosis. Lancet. 2021;398:1359–1376
Martín-Carbonero L, Sánchez-Somolinos M, García-Samaniego J, Núñez MJ, González-Lahoz J, Soriano V. Reduction in liver-related hospital admissions and deaths in HIV-infected patients since the year 2002. J Viral Hepat. 2006;13:851–857
Soriano V, Vispo E, Sierra-Enguita R, de Mendoza C, Fernández-Montero JV, Labarga P. Efficacy of prolonged tenofovir therapy on hepatitis delta in HIV-infected patients. AIDS. 2014;28:2389–2394
Spanish Statistics Institute. Available online: http://www.ine.es/en/index.htm (Accessed on 15 Dec 2021)
Grupo de trabajo del estudio de prevalencia de la infección por hepatitis C en población general en España; 2017–2018. Resultados del 2º Estudio de Seroprevalencia en España (2017–2018). Ministerio de Sanidad, Consumo y Bienestar Social; 2019. https://www.mscbs.gob.es/ciudadanos/enfLesiones/enfTransmisibles/sida/docs/INFORME_INFECCION_VHC_ESPANA2019.pdf. Accessed Mar 2022
Crespo J, Grupo técnico de cribado de la infección por el VHC. Screening guide for hepatitis C virus infection in Spain. Rev Esp Enferm Dig. 2021;113:81–82
Turnes J, Domínguez-Hernández M, Casado MA. Value and innovation of direct-acting antivirals: long-term health outcomes of the strategic plan for the management of hepatitis C in Spain. Rev Esp Enferm Dig. 2017;109:809–817
Cooke G, Andrieux-Meyer I, Applegate T, et al. Accelerating the elimination of viral hepatitis: a lancet gastroenterology & hepatology commission. Lancet Gastroenterol Hepatol. 2019;4:135–184
Cox A, El-Sayed M, Kao J, et al. Progress towards elimination goals for viral hepatitis. Nat Rev Gastroenterol Hepatol. 2020;17:533–542
Block T, Chang K, Guo J. Prospects for the global elimination of hepatitis B. Annu Rev Virol. 2021;8:437–458
Soriano V, Barreiro P, Cachay E, Kottilil S, Fernandez-Montero JV, de Mendoza C. Advances in hepatitis B therapeutics. Ther Adv Infect Dis. 2020;7:2049936120965027
Soriano V, Alvarez C, Edagwa B, et al. Ultra-long acting (XLA) antivirals for chronic viral hepatitis. Int J Infect Dis. 2021;114:45–50